# US 2015/0030551 A1 · Benzopyran compounds as melanogenesis modifiers and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0030551 A1
- Document ID: US20150030551A1
- Status: Published application
- Kind: A1
- Application number: 14/457,634
- Filed: 2014-08-12
- Published: 2015-01-29
- Earliest claimed: 2011-01-27
- Assignees: New York University
- Inventors: Seth J. ORLOW
- Web page: https://patentgrep.com/patent/US20150030551A1

## CPC

- C07D 493/04: Ortho-condensed systems
- A61K 8/498: {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- A61K 8/9789: Magnoliopsida [dicotyledons]
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 36/60: Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/00: Drugs for dermatological disorders
- A61Q 5/00: Preparations for care of the hair
- A61Q 19/02: for chemically bleaching or whitening the skin
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Provided are benzopyran compounds of formula I, for example, pomiferin-3′,4′-dimethyl ether, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation. wherein R3, R4, R5, R6, R7 and R8 are described herein. Also provided are plant extracts containing a compound of formula I, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.

## Claims

### Claim 1

A method for inhibiting melanogenesis or a method for promoting skin lightening comprising administering to a mammal an effective amount of a compound of formula I:
wherein
R3 is selected from H, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted aryl; and substituted or unsubstituted heteroaryl;
R4 is selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted phenyl;
each R5, R6′ and R8 is independently selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted phenyl;
R7 is selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or heterocycloalkyl; or R7 is —P(═O)(alkoxy)2, or —P(═S)(alkoxy)2; or
R6 and R7 or R7 and R8 are joined to form a 5- or 6-membered heterocycloalkyl or heterocycloalkenyl; and the heterocycloalkyl or heterocycloalkenyl is unsubstituted or substituted with one more groups selected from alkyl, alkenyl, hydroxyalkyl, acyloxyalkyl, hydroxy, and alkoxy;
or pharmaceutically acceptable salts, solvates, isomers, tautomers, metabolites, analogs, isotopic variants or prodrugs thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein the compound is of formula I; and R7 is selected from H, substituted or unsubstituted alkyl, and substituted or unsubstituted alkenyl.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is of formula I; and R3 is H, Cl, alkyl, or substituted or unsubstituted phenyl.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound is of formula I; and R4 is H, Cl, alkyl, or substituted or unsubstituted phenyl.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound is of formula I; and R5 is H, Cl, alkyl, hydroxy, or alkoxy.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound is of formula I; and R6 is H, Cl, alkyl, alkenyl, hydroxy, alkoxy, or alkenyloxy.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound is of formula I; and R8 is H, Cl, alkyl, alkenyl, hydroxy, alkoxy, or alkenyloxy.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method of claim 1 wherein the compound is of formula I; each R3, R4, R5, R6 is H; R7 is as in claim 1; and R8 is substituted or unsubstituted alkenyl.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The method of claim 1 wherein the compound is of formula IIa, IIb, IIc, or IId:
or a pharmaceutically acceptable salt, solvate or prodrug thereof, and stereoisomers, tautomers and isotopic variants thereof; and wherein
R4, R5, and R6 are as in claim 1;
R3 is selected from halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl;
R8 is selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl; and
each R6a, R7a, R7b, and R8a is independently selected from H, alkyl, hydroxyalkyl, or alkenyl.

### Claim 24 (depends on 1)

The method of claim 1 wherein the compound is of formula IIIa, IIIb, IIIc or IIId:
or a pharmaceutically acceptable salt, solvate or prodrug thereof, and stereoisomers, tautomers and isotopic variants thereof; and wherein
R4, R5, and R6 are as in claim 1;
R3 is selected from halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl;
R8 is selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl; and
each R6a, R7a and R7b is independently selected from H, alkyl, hydroxyalkyl, or alkenyl.

### Claim 25 (depends on 1)

The method of claim 1 wherein the compound is of formula IV:
or a pharmaceutically acceptable salt, solvate or prodrug thereof, and stereoisomers, tautomers and isotopic variants thereof; and wherein
R4, and R5 are as in claim 1;
R3 is selected from halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl;
R8 is selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl; and
each R6a and R7a is independently selected from H, alkyl, or alkenyl.

### Claim 26 (depends on 1)

The method of claim 1, wherein R4 is H, Cl, alkyl, hydroxy, alkoxy, or substituted or unsubstituted phenyl.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36 (depends on 1)

The method of claim 1 wherein the compound is of formula Va, or Vb:
or a pharmaceutically acceptable salt, solvate or prodrug thereof, and stereoisomers, tautomers and isotopic variants thereof; and wherein
R4, R5, and R6 are as in claim 1;
R3 is selected from halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl;
R8 is selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl.

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46 (depends on 1)

The method of claim 1 wherein the compound is of formula VIa, or VIb:
or a pharmaceutically acceptable salt, solvate or prodrug thereof, and stereoisomers, tautomers and isotopic variants thereof; and wherein
R3 is selected from halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl.

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49 (depends on 1)

The method of claim 1 wherein the compound is of formula VIIa, VIIb, or VIIc:
or a pharmaceutically acceptable salt, solvate or prodrug thereof, and stereoisomers, tautomers and isotopic variants thereof.

### Claim 50 (depends on 1)

The method of claim 1, wherein the compound is osajin-4′methylether, or pomiferin-3′,4′-dimethyl ether.

### Claim 51 (depends on 1)

The method of claim 1, wherein the compound is warangalone or warangalone-4′-methylether.

### Claim 52 (depends on 1)

The method of claim 1, further comprising an additional active agent, and said additional active agent is selected from a pharmacological agent, a skin brightening agent or a skin lightening agent.

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58 (depends on 1)

A composition for inhibiting melanogenesis comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 1.

### Claim 59 (depends on 58)

The composition of claim 58, wherein the carrier is a parenteral, oral or topical carrier.

### Claim 60

(canceled)

### Claim 61 (depends on 58)

The composition of claim 58, wherein the effective amount of a melanogenesis inhibitor is from about 0.01 mg to about 100 mg.

### Claim 62

(canceled)

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65 (depends on 1)

A topical formulation comprising a composition for cosmetic or dermatological use, said composition comprising a compound of claim 1, and an acceptable carrier.

### Claim 66 (depends on 1)

A method for preventing, treating, ameliorating or managing a disease or condition involving undesired or aberrant melanogenesis, which comprises administering to a patient in need or desirous of such prevention, treatment, amelioration or management, a prophylactically or therapeutically effective melanogenesis-inhibiting amount of a compound of claim 1.

### Claim 67 (depends on 66)

The method of claim 66, wherein the compound or composition is administered to lighten or reduce pigmentation levels.

### Claim 68

(canceled)

### Claim 69 (depends on 1)

A method for altering or restoring pigmentation in mammalian skin, hair, wool or fur comprising administering to the mammalian skin, hair, wool or fur an amount of a composition comprising:
a) an amount, which is effective to alter or restore pigmentation in mammalian skin, hair, wool or fur, of one or more compounds of claim 1; and b) a suitable carrier, wherein the amount is effective to alter or restore pigmentation in mammalian skin, hair, wool or fur.

### Claim 70 (depends on 69)

The method of claim 69, wherein the compound is a melanogenesis inhibitor.

### Claim 71

(canceled)

### Claim 72 (depends on 1)

A combination of a compound as defined in claims 1, and a like-acting agent.

### Claim 73 (depends on 72)

The combination of claim 72, wherein said like acting agent is selected from a cosmetic ingredient and a pharmacologically active agent.

### Claim 74

(canceled)

### Claim 75

(canceled)

### Claim 76 (depends on 72)

A method for preventing, treating, ameliorating or managing a disease or condition involving undesired or aberrant melanogenesis, which comprises administering to a patient in need or desirous of such prevention, treatment, amelioration or management, a prophylactically or therapeutically effective melanogenesis-inhibiting amount of a combination of claim 72, wherein the like acting agent is a pharmacologically active agent.

### Claim 77 (depends on 76)

The method of claim 76, wherein the like-acting agent is a skin lightening compound.

### Claim 78 (depends on 72)

A method for altering or restoring pigmentation in mammalian skin, hair, wool or fur comprising administering to the mammalian skin, hair, wool or fur an amount, which is effective to alter or restore pigmentation in mammalian skin, hair, wool or fur, of a combination of claim 72, wherein the like-acting agent is a cosmetically active agent.

### Claim 79 (depends on 78)

The method of claim 78, wherein the like-acting agent is a skin lightening compound.

### Claim 80 (depends on 1)

A method for inhibiting melanogenesis comprising administering to a mammal an effective amount of a plant extract containing a compound of claim 1.

### Claim 81 (depends on 80)

The method of claim 80, wherein the plant extract is derived from the fruit of Maclura pomifera (Osage orange).

### Claim 82

(canceled)

### Claim 83 (depends on 80)

The method of claim 80, further comprising an additional active agent, and said additional active agent is selected from one or more of a pharmacological agent, a skin brightening agent or a skin lightening agent.

### Claim 84

(canceled)

### Claim 85

(canceled)

### Claim 86 (depends on 80)

The method of claim 80, wherein the effective amount of plant extract prevents, treats, ameliorates or manages a disease or condition involving undesired or aberrant melanogenesis.

### Claim 87

(canceled)

### Claim 88

(canceled)

### Claim 89

(canceled)

### Claim 90

(canceled)

### Claim 91 (depends on 80)

A topical formulation comprising a composition for cosmetic or dermatological use, said composition comprising a plant extract of claim 80 containing a prophylactically or therapeutically effective amount of compound of formula I.

### Claim 92 (depends on 80)

A combination of a plant extract of claim 80 and a like-acting agent.

### Claim 93 (depends on 92)

The combination of claim 92, wherein said like acting agent is selected from a cosmetic ingredient and a pharmacologically active agent.

### Claim 94

(canceled)

### Claim 95

(canceled)

### Claim 96

A method for inhibiting melanogenesis by melanocytes comprising administering to the melanocytes an effective amount of a plant extract containing compound of formula I in combination with a like-acting agent.

### Claim 97

(canceled)

### Claim 98

(canceled)

### Claim 99

(canceled)

### Claim 100

(canceled)

### Claim 101

(canceled)

### Claim 102

(canceled)

### Claim 103

(canceled)
